Autism and Stem Cell Treatments

AUTISM

There appears to be an increasing numbers of children afflicted with autism. This sharp escalation has been noted over the past thirty years. There have been all kinds of theories from allergies, yeast infestation, toxins and vaccines.

Pathological studies indicate that autism is due to a chronic inflammatory process in the brain. Most people now feel that some types of chemicals, toxins and vaccines are the causative agents. These could be from aluminum ingestion or absorption; lead exposure; chemicals in foods such as MSG and aspartane; mercury preservative in vaccines; reaction to measles or pertussis in vaccines.

There also appears to be some underlying immumological dysfunction with autism as exhibited by gastrointestinal symptoms associated with the condition.

Some scientists feel that there is genetic predisposition in patients with autism.

The classic case was described by Dr. Leo Kanner in 1943 with the child having poor eye contact; withdrawal behavior avoiding other children and adults; repeating words over and over again; moving back and forth in a chair; not communicating verbally.

Current treatments vary in their responsiveness. There is also a great variation in the subtypes of autism and their symptoms.

We approach the treatment as a chronic inflammatory condition of the brain with immunological dysfunction. The protocol consists of:

Chelation intravenous or oral.
Stimulation of endogenous stem cells in the brain with oral and injectable agents.
Delivery of neuron stem cells with nerve cell factor, brain neuropeptide, neurotrophin, glial derived neurotrophins, transformation growth factor, vascular growth factor either intravenously with an agent to penetrate the blood brain barrier or intrathecal spinal canal administration under local anesthesia.
Intravenous infusion of glutathione and neurological supplements.
Laboratory studies to check T and B lymphocytes; helper and suppressor cells; immunoglobulins IgA, IgG, IgM; IgG1;IgG2;IgG3;IgG4; cytokines

Patients will be given intravenous infusions to counterattack inflammatory cytokines and modulate antibodies attacking the neuroglia btrain cells.


		AUTISM There appears to be an increasing numbers of children afflicted with autism. This sharp escalation has been noted over the past thirty years. There have been all kinds of theories from allergies, yeast infestation, toxins and vaccines. Pathological studies indicate that autism is due to a chronic inflammatory process in the brain. Most people now feel that some types of chemicals, toxins and vaccines are the causative agents. These could be from aluminum ingestion or absorption; lead exposure; chemicals in foods such as MSG and aspartane; mercury preservative in vaccines; reaction to measles or pertussis in vaccines. There also appears to be some underlying immumological dysfunction with autism as exhibited by gastrointestinal symptoms associated with the condition. Some scientists feel that there is genetic predisposition in patients with autism. The classic case was described by Dr. Leo Kanner in 1943 with the child having poor eye contact; withdrawal behavior avoiding other children and adults; repeating words over and over again; moving back and forth in a chair; not communicating verbally. Current treatments vary in their responsiveness. There is also a great variation in the subtypes of autism and their symptoms. We approach the treatment as a chronic inflammatory condition of the brain with immunological dysfunction. The protocol consists of: Chelation intravenous or oral. Stimulation of endogenous stem cells in the brain with oral and injectable agents. Delivery of neuron stem cells with nerve cell factor, brain neuropeptide, neurotrophin, glial derived neurotrophins, transformation growth factor, vascular growth factor either intravenously with an agent to penetrate the blood brain barrier or intrathecal spinal canal administration under local anesthesia. Intravenous infusion of glutathione and neurological supplements. Laboratory studies to check T and B lymphocytes; helper and suppressor cells; immunoglobulins IgA, IgG, IgM; IgG1;IgG2;IgG3;IgG4; cytokines Patients will be given intravenous infusions to counterattack inflammatory cytokines and modulate antibodies attacking the neuroglia btrain cells.